Pfizer's RSV candidate receives FDA special status
The US health authority will accelerate its review of US-based Pfizer’s vaccine against RSV after granting it the Breakthrough Therapy Designation.
by marketwire, translated by daniel pedersen
Pfizer can look forward to a faster approval process for its vaccine against respiratory syncytial virus (RSV), as the US Food and Drug Administration (FDA) will fast-track its drug review, Bloomberg reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Moderna initiates phase III study of RSV vaccine
For subscribers
Glaxosmithkline halts RSV trial after safety recommendation
For subscribers
Bavarian Nordic on FDA special status: A huge validation
For subscribers
.jpg&w=384&q=75)
